Ha Na-Young, Shin Hyun Mu, Sharma Prashant, Cho Hyun Ah, Min Chan-Ki, Kim Hong-Il, Yen Nguyen Thi Hai, Kang Jae-Seung, Kim Ik-Sang, Choi Myung-Sik, Kim Young Keun, Cho Nam-Hyuk
Department of Microbiology and Immunology, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.
Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.
J Nanobiotechnology. 2016 Nov 26;14(1):76. doi: 10.1186/s12951-016-0229-2.
Zinc oxide nanoparticle (ZNP) has been applied in various biomedical fields. Here, we investigated the usage of ZNP as an antigen carrier for vaccine development by combining a high affinity peptide to ZNP.
A novel zinc oxide-binding peptide (ZBP), FPYPGGDA, with high affinity to ZNP (K = 2.26 × 10 M) was isolated from a random peptide library and fused with a bacterial antigen, ScaA of Orientia tsutsugamushi, the causative agent of scrub typhus. The ZNP/ZBP-ScaA complex was efficiently phagocytosed by a dendritic cell line, DC2.4, in vitro and significantly enhanced anti-ScaA antibody responses in vivo compared to control groups. In addition, immunization with the ZNP/ZBP-ScaA complex promoted the generation of IFN-γ-secreting T cells in an antigen-dependent manner. Finally, we observed that ZNP/ZBP-ScaA immunization provided protective immunity against lethal challenge of O. tsutsugamushi, indicating that ZNP can be used as a potent adjuvant when complexed with ZBP-conjugated antigen.
ZNPs possess good adjuvant potential as a vaccine carrier when combined with an antigen having a high affinity to ZNP. When complexed with ZBP-ScaA antigen, ZNPs could induce strong antibody responses as well as protective immunity against lethal challenges of O. tsutsugamushi. Therefore, application of ZNPs combined with a specific soluble antigen could be a promising strategy as a novel vaccine carrier system.
氧化锌纳米颗粒(ZNP)已应用于各种生物医学领域。在此,我们通过将一种高亲和力肽与ZNP结合,研究了ZNP作为疫苗开发的抗原载体的用途。
从一个随机肽库中分离出一种对ZNP具有高亲和力(K = 2.26×10 M)的新型氧化锌结合肽(ZBP),FPYPGGDA,并将其与一种细菌抗原,恙虫病东方体的ScaA融合,恙虫病东方体是恙虫病的病原体。ZNP/ZBP-ScaA复合物在体外被树突状细胞系DC2.4有效吞噬,并且与对照组相比,在体内显著增强了抗ScaA抗体反应。此外,用ZNP/ZBP-ScaA复合物免疫以抗原依赖的方式促进了分泌IFN-γ的T细胞的产生。最后,我们观察到用ZNP/ZBP-ScaA免疫提供了针对恙虫病东方体致死性攻击的保护性免疫,表明ZNP与ZBP偶联抗原复合时可作为一种有效的佐剂。
当与对ZNP具有高亲和力的抗原结合时,ZNPs作为疫苗载体具有良好的佐剂潜力。当与ZBP-ScaA抗原复合时,ZNPs可诱导强烈的抗体反应以及针对恙虫病东方体致死性攻击的保护性免疫。因此,将ZNPs与特定可溶性抗原结合应用可能是一种作为新型疫苗载体系统的有前景的策略。